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Abstract
HIV-infected individuals with severe immunodeficiency are at risk of opportunis-
tic infection (OI). Tuberculosis (TB) may occur without substantial immune
suppression suggesting an early and sustained adverse impact of HIV on
Mycobacterium tuberculosis (MTB)-specific cell mediated immunity (CMI). This
prospective observational cohort study aimed to observe differences in OI-specific
and MTB-specific CMI that might underlie this. Using polychromatic flow
cytometry, we compared CD4þ responses to MTB, cytomegalovirus (CMV),
Epstein-Barr virus (EBV) and Candida albicans in individuals with and without
HIV infection. MTB-specific CD4þ T-cells were more polyfunctional than virus
specific (CMV/EBV) CD4þ T-cells which predominantly secreted IFN-gamma
(IFN-g) only. There was a reduced frequency of IFN-g and IL-2 (IL-2)-dual-MTB-
specific cells in HIV-infected individuals, which was not apparent for the other
pathogens. MTB-specific cells were less differentiated especially compared with
CMV-specific cells. CD127 expression was relatively less frequent on MTB-specific
cells in HIV co-infection. MTB-specific CD4þ T-cells PD-1 expression was
infrequent in contrast to EBV-specific CD4þ T-cells. The variation in the inherent
quality of these CD4þ T-cell responses and impact of HIV co-infection may
contribute to the timing of co-infectious diseases in HIV infection.
Introduction
Mycobacterium tuberculosis (MTB) is a common cause of
HIV-related opportunistic infection (OI) in endemic [1]
and non-endemic areas [2]. Tuberculosis (TB) occurs
more frequently compared with HIV-uninfected individuals
in early [3, 4] treated [5] and advanced HIV infection. By
comparison, common OIs e.g. cytomegalovirus (CMV),
Epstein-Barr virus (EBV), andCandida albicans (C. albicans)
cause disease at defined later stages of CD4 cell depletion
[6–10]. Highly active antiretroviral therapy (HAART)
significantly reduces disease caused by C. albicans, EBV
and CMV but may be less effective in protecting against an
active TB infection. HAART significantly reduced TB
incidence in one study, although cases still occurred in
those who received HIV therapy [11]. Similar results in other
cohorts suggest that whilst incidence is reduced, MTB-
specific immunity may not completely regenerate with
HAART and TB incidence is not restored to background
levels [12]. These observations of the timing of different
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co-infections may reflect a unique effect of HIV co-infection
on MTB-specific immunity compared with other OIs that
occurs even in those with treated HIV infection.
Host responses to MTB, CMV, EBV and C. albicans share
a dependence on cell-mediated immunity (CMI), in parti-
cular antigen-specific CD4þ and CD8þ T-cell responses.
The differential impact of HIV co-infection may lie in its
effects on T-cell immunity; for example, some pathogen-
specific CD4þ T-cell subsets may be more vulnerable to
functional modulation or destruction by HIV infection than
others and some may be less able to regenerate during
immune restoration with HAART.
We hypothesised that in HIV co-infection MTB-specific
CMI would differ in frequency and phenotype from
CMI specific for other OIs. We compared pathogen-
specific responses to MTB, CMV, EBV and C. albicans in
individuals with and without HIV infection. Secondly,
we compared the differential impact of HIV infection
on the pathogen-specific responses within the same
individuals at the same time point. Whilst previous studies
have focused on T-cells specific for these OIs, none to our
knowledge have done so simultaneously with MTB-specific
T-cell immunity in HIV co-infected individuals. We used
polychromatic flow cytometry to quantify 7 non-overlapping
functional CD4þ T-cell subsets defined by IFN-gamma
(IFN-g), IL-2 (IL-2) and TNF-alpha (TNF-a) secretion. We
assessed these functional subsets for memory phenotype
(CD45RA, CCR7 expression), CD127 loss of expression of
which on CD4þ T-cells correlates with HIV disease
progression [13] and programmed death-1 (PD-1), a marker
of T-cell exhaustion. Expression of these two markers on
different OI pathogen-specific T-cells in the context of HIV
co-infection has not previously been investigated.
Results
MTB-specific CD4þ T-cells are more polyfunctional
than CMV-specific T-cells, which predominantly
secrete IFN-g-only
The demographics and HIV-infection clinical parameters of
participants are reported in Table 1; HIV-infected individu-
als were in the early or treated stages of infection (60% on
HAART) with a median (IQR) CD4 count of 455 cells/ml
(356,530) and HIV viral load (VL) of 10 copies/mL
(10,12,691). Those on HAART n¼ 6 had a median (IQR)
CD4 count of 372 (300,563) cells/ml and median (IQR) VL
of 10(10,10) RNA copies/mL i.e. below the threshold
of detection. The median (IQR) duration of HAART
was 3.4 years (0.8, 8.0). For those not on HAART,
(n¼ 4) the median (IQR) CD4 count was 500 (443, 528)
cells/ml and median (IQR) VL was 12,904 (3701, 37,621)
copies/mL.
All participants had evidence of MTB sensitisation based
on either a clinical ELISpot (T-Spot). TB or responses to the
MTB-specific antigens ESAT-6 and CFP-10 measured in a
laboratory IFN-g ELISpot. As shown in Figure 1 there was no
difference in frequency of spot forming cells between
individuals with or without evidence of HIV infection or
by antiretroviral therapy.
Pathogen-specific CD4þ responses to PPD, EBV and
CMV were compared using Boolean gating to create 7 non-
overlapping CD4þ cell subsets (Fig. 2A). All participants
had a CD4þ T-cell response to PPD and EBV and all but
one to CMV in at least one functional cytokine subset. In
general the EBV-specific response was low frequency and
monofunctional, the CMV-specific response was high
frequency and monofunctional and the MTB-specific
response was intermediate frequency and polyfunctional.
PPD induced a higher frequency of CD4þ cells secreting
TNF-a-alone, with IL-2 and with IFN-g and IL-2 compared
with EBV and CMV in those without evidence of HIV
infection, with similar trends in those with HIV infection
(Fig. 2B).
CMV induced a higher frequency of IFN-g-only secreting
CD4þ cells than EBV in those without evidence of
HIV infection and a higher frequency than MTB- and
EBV-specific IFN-g-only CD4þ cells in those with HIV
infection (Fig. 2B). A principal impact of HIV was
to attenuate the frequency of the MTB-specific IFN-g
and IL-2-dual response but not other pathogen-specific
IFN-g and IL-2-dual responses (Fig. 2B). When com-
pared with those with HIV infection, those without
evidence of HIV infection had relatively more frequent
CD4þ MTB-specific cells secreting IFN-g and IL-2
(P¼ 0.015).
MTB-specific responses derive mostly from the
central memory T-cell pool whereas responses to
other OIs are more differentiated
We next examined the phenotype of CD4þ pathogen-
specific T-cells according to whether they were naı¨ve
(CD45RAþCCR7þ), central memory; TCM (CD45RA
CCR7þ), effector memory; TEM (CD45RACCR7) or
CD45RAþ effector memory; TEMRA (CD45RAþCCR7)
(Fig. 3A). MTB-specific CD4þ functional effector cells
secreting IFN-g and TNF-a were enriched in the TCM subset
whereas responses to EBV, CMV and for the most part
C. albicans were more differentiated. This was striking for
IFN-g-only secreting CD4þ cells responding to CMV and
C. albicans, which were mostly TEM (Fig. 3B). Similarly
CD4þ cells secreting IFN-g and TNF-awere enriched in the
TEM subset for CMV, EBV and C. albicans responses but not
for PPD, which were enriched in the TCM subset (Fig. 3C).
These CMV-specific CD4þ cells were more differentiated in
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HIV co-infection than PPD and/or EBV (supplementary
Fig. 1). CD4þ cells secreting IL-2 with or without other
cytokines tended to derive from the TCM subset irrespective
of pathogen specificity for example IFN-g and IL-2-dual
secreting CD4þ cells (Fig. 3D). The presence of HIV
co-infection did not affect the proportion of antigen-specific
cells that were TCM for any pathogen-specificity (data not
shown).
CD127 expression was greatest on MTB-specific
cells
Antigen-specific CD4þ cells were examined for expression
of CD127 (Fig. 4A). MTB-specific CD4þ functional effector
cells secreting IFN-g alone, TNF-a alone or IFN-g and
TNF-a more frequently expressed CD127 compared
with EBV and/or CMV-specific cells in those without
evidence of HIV co-infection (Fig. 4B). These differences
were not seen in HIV co-infection (data not shown).
In HIV co-infection CD127 was relatively less fre-
quently expressed on MTB-and CMV-specific IFN-g and
IL-2-dual-secreting cells compared with EBV-specific
CD4þ cells than in those without evidence of HIV infection
(Fig. 4C).
PD-1 expression on MTB-specific cells was
significantly lower than other OIs
Antigen-specific cells were next examined for expression of
PD-1 (Fig. 5A). Across most subsets especially those
secreting IFN-g, EBV-specific CD4þ cells more frequently
expressed PD-1 than MTB-specific CD4þ cells in those with
and without evidence of HIV co-infection for example
Table 1. Demographics and test results of participants.
HIV No HIV
10 % or IQR 11 % or IQR
Median (IQR) age 37 (24,40) 34 (30,36)
Male 6 (60.0) 4 (36.4)
Female 4 (40.0) 7 (63.6)
Black African 8 (80.0) 6 (54.5)
Asian 0 (0.0) 3 (27.3)
Caucasian/Central S America 2 (20.0) 2 (18.2)
HIV positive 10 (100.0) 0 (0.0)
HIV negative 0 (0.0) 6 (54.5)
HIV untesteda 0 (0.0) 5 (45.5)
Median (IQR) CD4 cells/mlb 455 (356;530) NA NA
Median (IQR) CD4% 25 (15,30) NA NA
Median (IQR) HIV RNA copies/mL 10 (10;12691) NA NA
HAART treated 6 (60.0) NA NA
HAART untreated 4 (40.0) NA NA
BCG vaccinated 9 (90.0) 8 (72.7)
BCG unvaccinated 0 (0.0) 2 (18.2)
BCG history unknown 1 (10.0) 1 (9.1)
T.Spot þ/ TST positive 10c (100.0) 11 (100.0)
Proportion with positive total response to
PPD 10/10 (100.0) 11/11 (100.0)
EBV infected cell extract 10/10 (100.0) 11/11 (100.0)
CMV infected cell extract 10/10 (100.0) 10/11 (90.9)
Candida albicans 6/6 (100.0) 10/10 (100.0)
IQR¼ interquartile range.
aLocal clinical guidelines at the time did not specify testing for HIV infection in individuals undergoing screening for latent tuberculosis infection, however
all those without an HIV test had normal CD4/CD8 ratios in the experimental assay (>1.2).
bCD4 counts according to standardized clinical protocols for patients with HIV infection were not available for HIV-uninfected individuals.
cOne individual had received 3 days chemoprophylaxis treatment at the time of recruitment.
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IFN-g-only secreting cells (Fig. 5B). In contrast to other
pathogen-specific CD4þ cells, MTB-specific T-cells infre-
quently expressed PD-1 across all subsets except IL-2-only
secreting cells, where expression of PD-1 tended to be
infrequent in response to EBV, CMV and C. albicans
(Supplementary Fig. 2). CMV-specific cells expressed PD-1
relatively more frequently in those with HIV co-infection in
polyfunctional subsets secreting IFN-g e.g. IFN-g and IL-2-
dual secreting cells (Fig. 5C).
Discussion
In our cohort of mostly treated or relatively immunocom-
petent HIV-infected individuals and those without evidence
of HIV co-infection, MTB-specific T-cells were more
frequently polyfunctional and less differentiated than
virus-specific T-cells. CMV and EBV-specific T-cells were
more frequently monofunctional (dominated by IFN-g)
and more differentiated than MTB-specific cells. HIV
co-infection was associated with an increased frequency of
CMV-specific IFN-g-only and TNF-a-only CD4þ cells
compared with PPD. It was also associated with the relative
loss of CD127 expression on CD4þMTB-specific functional
effector cells secreting IFN-g and/or TNF-a.
Compared to other pathogens, MTB-specific T-cells were
uniquely impacted by HIV co-infection, as there was
attenuation of the frequency of the CD4þ IFN-g and
IL-2-dual response. These cells were principally derived from
the TCM subset irrespective of pathogen specificity and
MTB-specific IFN-g and IL-2-dual secreting CD4þ cells
expressed relatively little CD127 in HIV co-infection and
very little PD-1 regardless of HIV infection. Even in
individuals with the early or treated stages of HIV infection
the incidence of active TB infection is elevated [4, 12, 14].
The incidence of other OIs including EBV, CMV and C.
albicans are conversely more closely associated with CD4
count decline and HAART may therefore have a relatively
more protective effect. Some T-cell subsets may be especially
vulnerable to HIV-mediated destruction contingent upon
cytokine secretion e.g. IL-2, or pathogen-specificity or a
combination of the two. This may be related to the absence
of other cytokines such as MIP-1b, binding HIV co-
receptors [15–17]. Although we did not measure CCR5
expression, the IL-2-secreting polyfunctional MTB-specific
CD4þ cell response could be more vulnerable to HIV than
pathogen-specific CMI where CD4þ functional effectors
predominate e.g. CMV. Immune competence to these OIs
may therefore be relatively resilient until CD4 count has
significantly declined.
Our finding that MTB-specific IFN-g and IL-2-dual-
secreting cells were significantly less frequent in our HIV
co-infected cohort with relatively preserved or reconstituted
immunity suggests that these cells may be both especially
vulnerable in early HIV infection and fail to reconstitute
with HAART. Antigen-specific T-cells secreting IL-2 with or
without IFN-g have been associated with containment (or
resolution) of viral infections [18–20] and TB [21–23]. The
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Figure 1. IFN-g ELISpot responses. Graphs show log10 frequency of spot
forming cells per 250,000 PBMCs responding to overnight stimulation
with MTB-speciﬁc antigens, ESAT-6 (top graph) and CFP-10
(bottom graph) in all participants without evidence of HIV infection
(left column) with HIV infection on highly active antiretroviral therapy
(HAART, middle column) and not on HAART (right column). Kruskal–
Wallis test with Dunn's post-test comparison showed no signiﬁcant
difference between the three groups for either antigen. One untreated
individual's assay failed at T0 but was positive at T1. Two individuals
had a positive response to ESAT-6 and/or CFP-10 in the commercial
assay only.
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total MTB-specific IFN-g response protects against the
development of active TB in HIV-infected individuals [24]
and MTB-specific functional effector and polyfunctional
cells were less frequent in the lung of HIV-infected
individuals [25]. This relationship was not observed for
other functional subsets or for other pathogens, pinpointing
CD4þ IFN-g and IL-2-dual-secreting cells as a possible
correlate of MTB containment in vivo. The resulting
potential for loss of immunoprotection and replication
and spread of MTB remains to be explored in animal models
or larger longitudinal cohorts.
Expression of CD127 may indicate potential for cellular
survival. The IL-7 receptor heterodimer prevents cellular
apoptosis through IL-7 signalling [26]. T-cell activation
causes down-regulation of CD127 [27], and relatively low
levels of expression were seen on PPD stimulated CD4þ cells
Figure 2. Frequency distribution of functional subset responses in participantswith andwithout HIV co-infection. Representative gating strategy showing
results from an individual without evidence of HIV infection. PBMCs were stimulated overnight with PPD and stained for intracellular and phenotypic
markers before collection on an LSR II ﬂow cytometer. Data were gated on live cells, singlets, lymphocytes, CD3þ cells and then CD4þ and CD8þ cells.
CD4þ cells were then gated for expression of IFN-g, IL-2, and TNF-a and Boolean gating used to create 7 non-overlapping subsets for example IFN-g and
IL-2 dual producing CD4þ cells (A). Graphs show frequency of all 7 CD4þ cytokine subsets responding to PPD, EBV and CMV in those with and without
evidence of HIV infection. Those with HIV infection not on HAART are marked with an asterisk (B). Each line represents a comparison of the response to
multiple pathogens within a single individual. Analysis using Friedman test and Dunn's Multiple Comparison test: P< 0.05, P< 0.01, P< 0.001.
Analysis shows all those with a positive response to at least one of the three antigens, non-responders to all three antigens were excluded. Experiments
were conducted in n¼ 10 HIV, n¼ 11 non-HIV. All individuals had a positive response in each cytokine subset to at least one antigen except in the
following cases; for theHIV groupCD4þ IL-2-only-secreting cells n¼ 8 andCD4þ TNF-a-only secreting cells n¼ 6 had a positive response and for the non-
HIV group CD4þ IL-2-only-secreting cells n¼ 8 and CD4þ TNF-a-only secreting cells n¼ 9 had a positive response. When compared with those with HIV
infection, those without HIV infection had relatively more frequent PPD-speciﬁc cells secreting IFN-g and IL-2 (P¼ 0.015).
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although they were predominantly TCM. In those without
HIV co-infection PPD-specific CD4þ cells secreting IFN-g
with or without TNF-a and expressing CD127 were
relatively more frequent but this expression was reduced
in HIV co-infection indicating that these cells might
be relatively short-lived. Furthermore CD4þ PPD-specific
cells secreting IFN-g and IL-2 and expressing CD127
were relatively less frequent in HIV co-infection indicat-
ing another potential mechanism of the loss of this key
subset.
Our data indicate pathogen-related variance in expression
of CD45RA and CCR7 of some subsets analogous to work on
CD8þ cells [28, 29] and CD4þ cells [30]. CD4þ cells
secreting IL-2 with or without other cytokines were
principally derived from the TCM subset irrespective of
pathogen specificity. The most striking differences were in
IFN-g-only, TNF-a-only and IFN-g and TNF-a dual-
secreting CD4þ cells where the PPD-specific response was
mostly TCM and responses to other pathogens especially
CMV were more differentiated. There was a dichotomy
between the relationship of pathogen specificity, cell
phenotype and functionality between cells that secreted
IL-2 and those that did not. Whilst linked T-cell
functionality and memory phenotype is well established in
several models [31], our data suggest a more flexible
relationship between surface phenotype and cytokine
expression in human HIV and MTB coinfection. As we
showed previously, this may be related to antigen bur-
den [32]. In HIV co-infection there was enrichment of TEM
CMV-specific cells secreting IFN-g, consistent with an HIV-
associated subclinical increase in CMV antigen load driving
the size and differentiation of the CMV-specific effector-
memory cellular immune response.
We observed significant pathogen-specific differences in
the frequency of CD4þ PD-1 expressing cells. The PD-1
pathway plays a role in T-cell exhaustion in HIV [33, 34] and
MTB [35] and may be tissue protective [36]. Our data
suggest a less significant role for PD-1 on CD4þ MTB-
specific T-cells in LTBI where antigen load is low. It is
unlikely that our cohort had a high EBV viral load however,
which begs a different explanation of the high frequency of
CD4þ EBV-specific PD-1þ cells we observed. The frequency
of cells expressing PD-1 may be an inherent quality of the
pathogen-specific T-cell response that could have a direct
relationship to IFN-g secretion that varies by pathogen. The
generally low absolute frequency of EBV-specific CD4þ
T-cells but high proportion of PD-1-expressing T-cells
within them is notable and in contrast to other pathogens. In
those without HIV co-infection a higher percentage of
several EBV-specific CD4þ T-cell subsets expressed PD-1
than CMV-specific cells. This suggested that in HIV co-
infection these CMV-specific subsets were more likely to
express PD-1 again consistent with an HIV-related increase
in the CMV immune response.
Our observations bring together detailed comparative
analysis of CMI to opportunistic pathogens, and the OI-
specific impacts of HIV infection. Our study was limited
by the small cohort size, which included a mostly treated
Figure 3. Continued
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HIV-group. Therefore, while we were able to demonstrate
significant differences we were unable to prove the
absence of weaker associations, which would require a
larger cohort. Pathogen-specific differences that we observed
in the natural frequency and phenotype of the CD4þ
response may underlie inherent immune vulnerabilities in
HIV co-infection and shape the timing of opportunistic
infections.
Figure 3. Comparison of memory phenotype in each CD4þ functional subset: Representative gating stategy for one individual without HIV infection.
Contour plots showCCR7 andCD45RA expression of from left to right bulk CD4þ cells, IFN-g and IL-2 dual- and IL-2 only secreting CD4þ cells in response
to overnight stimulation with PPD (top row) and CMV (bottom row) (A). Graphs show from left to right, proportion of cells that were naïve
(CD45RAþCCR7þ), TCM (CD45RACCR7þ), TEM (CD45RACCR7) and TEMRA (CD45RAþCCR7) in each CD4þ functional subset responding to EBV,
CMV, C. albicans and PPD in all participants. Graphs showCD4þ cells secreting IFN-g alone (B), IFN-g and TNF-a (C) and those secreting IFN-g and IL-2 (D).
Graphs show only those with a positive response in each functional subset (number indicated above graph). p values show Friedman test with Dunn's
Multiple Comparison test; P< 0.05, P< 0.01, P< 0.001.
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Figure 4. Comparison of CD4þ functional subsets that were CD127þ: Representative gating strategy, using ﬂuorescence minus one (FMO) control to
gate on CD127þCD4þ cells from each Boolean gated subset. CD4þ cells secreting IL-2 only in response to overnight stimulation with PPD (left) and CMV
cell extract (middle) are shown with the FMO (right) (A). Graphs show percentage of cells in each CD4þ functional effector subset that were CD127
positive in those without evidence of HIV co-infection (B). Graphs show percentage of CD4þ cells secreting IFN-g and IL-2 that expressed CD127 in those
without evidence of HIV infection (left column) and with HIV infection (right column) (C). Each line represents a comparison of the response to multiple
pathogens within a single individual. Analysis using Friedman test and Dunn's Multiple Comparison test P< 0.05, P< 0.01, P< 0.001. Analysis
shows all those with a positive response to at least one of the three antigens, non-responders were excluded (number indicated above graph).
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Materials and Methods
Case selection
Individuals undergoing clinical screening for or with risk
factors for latent TB infection e.g. healthcare work with TB
patients or history of exposure to TB, were recruited from
three London, UK clinical centres from 2008 to 2010.
Participants were 18 years and provided written informed
consent, National Research Ethics Service approval (07/
H0712/85). n¼ 21 individuals with and without HIV
infection were selected for immunological studies. Evidence
of immune sensitisation to MTB was defined as a positive
IFN-g MTB-specific ELIspot (either commercial or labora-
tory assay) and no evidence of active TB. Those with a
previous history of treated TB infection and no re-exposure
were excluded. Evidence of HIV infection was determined by
serology in a clinical pathology laboratory. The presence of
cellular immune responses to the OI pathogen-specific
antigens on flow-cytometry (see below) for CMV, EBV or
C. albicans, was deemed as evidence of immune sensitisa-
tion with the respective pathogens. Non-responders were
excluded from analysis where indicated.
IFN-g ELISpot
Was performed as previously described [37] in singlicate
using fresh or frozen peripheral blood mononuclear cells
(PBMCs) and cells left unstimulated or stimulated with
Figure 5. Comparison of percentage of CD4þ pathogen-speciﬁc subsets expressing PD-1. Representative gating strategy, using ﬂuorescence minus one
(FMO) control to gate on PD-1þ CD4þ cells from each Boolean gated subset. CD4þ cells secreting IFN-g only in response to overnight stimulation with
PPD (left) and EBV cell extract (middle) are shownwith the FMO (right) (A). Graphs show frequency of CD4þ cells expressing IFN-g alone (B) and IFN-g and
IL-2 (C) that were PD-1 positive in participants with and without evidence of HIV infection. Only those with a positive response to any antigen were
included (number indicated above graph). Each line represents a comparison of the response to multiple pathogens within a single individual. p values are
results of Friedman test and Dunn's Multiple Comparison test P< 0.05, P< 0.01, P< 0.001.
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phytohaemagglutinin (PHA), purified protein derivative
(PPD) and pools of MTB-specific 15-mer overlapping
peptides including ESAT-6 and CFP-10 (10mg/mL per
peptide final concentration). Positive responders were those
with a test well that was greater than or equal to twice the
negative control well and at least 5 spot forming cells greater
than the negative control well.
Intracellular cytokine staining
Performed as previously described [32]. Briefly, thawed
PBMCs were cultured for 16 h (378C 5% CO2) in 10%
human serum in Roswell Park Memorial Institute medium
(RPMI) at a concentration of 1 107 cells/mL. Cells were left
unstimulated or stimulated with PMA-Ionomycin, PPD,
EBV infected cell extract, CMV infected cell extract or C.
albicans bulk antigen. After 2 h, monensin (2mM final
concentration) was added. Cells were washed and stained
with a dead cell marker (LIVE/DEAD1 Fixable Dead Cell
Stain Kits, aqua, Invitrogen, Paisley, UK) for 30min at 48C in
PBS, washed in PBS and placed in FC block buffer (10%
human serum in FACS solution) for 20min at 48C. Staining
was with a pre-titrated and optimised antibody cocktail with
fluorochrome-conjugated antibodies against CD3-APC-
Alexa Fluor1750, CD4-Qdot1605 and CD45RA- CD4-
Qdot1655 (Invitrogen), CD8-APC, CCR7-PE-CyTM7 and
CD127-FITC (BD Biosciences) and PD-1-PerCP/Cy5.5
(BioLegend, London UK). The cells were fixed and
permeabilised using BD Cytofix/CytopermTM Fixation/
Permeabilisation kit (BD Biosciences) for 20min at 48C.
The cells were washed twice with Perm/Wash solution (BD
Biosciences, Oxford, UK) then stained with pre-titrated
fluorochrome-conjugated antibodies in Perm/Wash solu-
tion with IFN-g-V450, IL-2-PE and TNF-a-AlexaFluor 700
(BD Biosciences) for 30min 48C. The cells were acquired
straightaway using an LSR-II flow cytometer and 1 106
events acquired where possible. Anti-Rat and Anti-Mouse Ig
compensation beads (BD Biosciences) were used to set
compensation parameters. Fluorescence minus one (FMO)
controls were used to set gates.
Antigens
PPD was obtained from Serum Statens Institute and
resuspended in RPMI and used at a final concentration of
16.7mg/mL. EBV-infected (Human B cell) cell extract, virus
strain P3HR1 (EV012 EastCoast Bio, final concentration
10mg/mL), CMV-infected cell (Normal Human Dermal
Fibroblast) extract, virus strain AD169 (CV001 EastCoast
Bio, final concentration 10mg/mL) and C. albicans bulk
antigen (BA117VS virion\serion, final concentration
20mg/mL). The reproducibility and acceptability of using
these extracts to study cellular EBV and CMV responses
has been established [38]. In some participants PBMC
availability was insufficient for responses to C. albicans to
be tested.
Data analysis
The data were analysed on FlowJo version 9.2 FlowJo LLC
385 Williamson Way, Ashland OR 97520 and gated as
previously described, briefly dead cells and doublets were
excluded, then lymphocytes chosen, cells were gated as
CD3þ then CD4þ and then Boolean gating used to create
seven non-overlapping subsets e.g. CD4þIFN-g and IL-2-
dual secreting cells [32]. All responses were normalised to the
unstimulated, fully stained control. Positive responders
were defined as those with a response that was 2 times the
background and with a frequency of >0.001 CD4þ cells.
Each subset was gated for expression of CD45RA and CCR7,
CD127 and PD-1.
Statistical analysis
Was conducted using Prism 5 for MAC OSX. The Mann–
Whitney U test was used for two sample comparisons.
A Friedman test with Dunn’s post-test comparison was used
for non-parametric continuous data generated from
repeated measures within individuals.
Acknowledgements
Dr Lee Potiphar, Mr Samuel Bremang, the staff at the
Jefferiss Wing Clinic, St Mary’s Hospital, London and
Northwick Park Hospital GUM clinic, Harrow.
Conflict of Interest
The ESAT-6/CFP-10 ELISpot was commercialised by an
Oxford University spin-out company (Oxford Immunotec
Ltd, Abingdon, UK) in which Oxford University and
Professor Lalvani have a minority share of equity and
entitlement to royalties.
Author Contribution
KMP, conceived and designed the study, designed experi-
ments, recruited participants, analysed data and wrote the
paper; DJMS, designed experiments and analysed data; GSC,
designed the study and wrote the paper; MSK, designed the
study and wrote the paper; OMK provided clinical support;
LG, recruited participants; RDS, designed experiments and
aided data analysis; GPT, designed the study, aided data
analysis and wrote the paper; AL, conceived and designed the
study, aided data analysis and wrote the paper.
K. M. Pollock et al. Immunity inflammation and disease
© 2015 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 151
References
1. WHO, TB/HIV facts 2011.
2. ECDC/WHO, Tuberculosis surveillance in Europe 2009.
3. Oni, T., R. Burke, R. Tsekela, N. Bangani, R. Seldon, H.P.
Gideon, K. Wood, K. A.Wilkinson, T. H. Ottenhoff, and R. J.
Wilkinson. 2011. High prevalence of subclinical tuberculosis
in HIV-1-infected persons without advanced immunodefi-
ciency: implications for TB screening. Thorax 66:669–673.
4. Sonnenberg, P., J. R. Glynn, K. Fielding, J. Murray, P.
Godfrey-Faussett, and S. Shearer. 2005. How soon after
infection with HIV does the risk of tuberculosis start to
increase? A retrospective cohort study in South African gold
miners. J. Infect. Dis. 191:150–158.
5. Lawn, S. D., A. D. Harries, B. G. Williams, R. E. Chaisson, E.
Losina, K. M. De Cock, and R. Wood. 2011. Antiretroviral
therapy and the control of HIV-associated tuberculosis. Will
ART do it? Int. J. Tuberc. Lung Dis. 15:571–581.
6. Bronke, C., N. M. Palmer, C. A. Jansen, G. H. Westerlaken,
A. M. Polstra, P. Reiss, M. Bakker, F. Miedema, K. Tesselaar,
and D. van Baarle. 2005. Dynamics of cytomegalovirus
(CMV)-specific T cells in HIV-1-infected individuals pro-
gressing to AIDS with CMV end-organ disease. J. Infect. Dis.
191:873–880.
7. Petrara, M. R., R. Freguja, K. Gianesin, M. Zanchetta, and A.
De Rossi. 2013. Epstein-Barr virus-driven lymphomagenesis
in the context of human immunodeficiency virus type 1
infection. Front. Microbiol. 4:311.
8. Engels, E. A., R. M. Pfeiffer, O. Landgren, and R. D. Moore.
2010. Immunologic and virologic predictors of AIDS-related
non-hodgkin lymphoma in the highly active antiretroviral
therapy era. J. Acquir. Immune Defic. Syndr. 54:78–84.
9. Owotade, F. J., M. Patel, T. R. Ralephenya, and G. Vergotine.
2013. Oral Candida colonization in HIV-positive women:
associated factors and changes following antiretroviral
therapy. J. Med. Microbiol. 62:126–132.
10. Nkuize, M., S. DeWit, V.Muls, M. Arvanitakis, andM. Buset.
2010. Upper gastrointestinal endoscopic findings in the era of
highly active antiretroviral therapy. HIV Med. 11:412–417.
11. Miranda, A., M. Morgan, L. Jamal, K. Laserson, D. Barreira,
G. Silva, J. Santos, C. Wells, P. Paine, and D. Garrett. 2007.
Impact of antiretroviral therapy on the incidence of
tuberculosis: the Brazilian experience, 1995–2001. PLoS
ONE 2:e826.
12. Lawn, S. D. L. G. Bekker, and R. Wood. 2005. How effectively
does HAART restore immune responses to Mycobacterium
tuberculosis? Implications for tuberculosis control. AIDS
19:1113–1124.
13. Dunham, R. M., B. Cervasi, J. M. Brenchley, H. Albrecht, A.
Weintrob, B. Sumpter, J. Engram, S. Gordon, N. R. Klatt, I.
Frank, et al. 2008. CD127 and, CD25 expression defines
CD4þ T cell subsets that are differentially depleted during
HIV infection. J. Immunol. 180:5582–5592.
14. Lawn, S. D., M. Badri, and R. Wood. 2005. Tuberculosis
among HIV-infected patients receiving HAART: long term
incidence and risk factors in a South African cohort. AIDS
19:2109–2116.
15. Geldmacher, C., N. Ngwenyama, A. Schuetz, C. Petrovas,
K. Reither, E. J. Heeregrave, J. P. Casazza, D. R. Ambrozak,
M. Louder, W. Ampofo, et al. 2010. Preferential infection
and depletion of Mycobacterium tuberculosis-specific
CD4 T cells after HIV-1 infection. J. Exp. Med. 207:2869–
2881.
16. Hu, H., M. Nau, P. Ehrenberg, A. L. Chenine, C. Macedo, Y.
Zhou, Z. J. Daye, Z. Wei, M. Vahey, N. L. Michael, et al. 2013.
Distinct gene-expression profiles associated with the suscep-
tibility of pathogen-specific CD4 T cells to HIV-1 infection.
Blood 121:1136–1144.
17. Day, C. L., N. Mkhwanazi, S. Reddy, Z. Mncube, M. van der
Stok, P. Klenerman, and B. D. Walker. 2008. Detection of
polyfunctional Mycobacterium tuberculosis-specific T cells
and association with viral load in HIV-1-infected persons.
J. Infect. Dis. 197:990–999.
18. Harari, A., F. Vallelian, P. R. Meylan, and G. Pantaleo. 2005.
Functional heterogeneity of memory CD4 T cell responses in
different conditions of antigen exposure and persistence.
J. Immunol. 174:1037–1045.
19. Harari, A., S. Petitpierre, F. Vallelian, and G. Pantaleo. 2004.
Skewed representation of functionally distinct populations of
virus-specific CD4 T cells in HIV-1-infected subjects with
progressive disease: changes after antiretroviral therapy.
Blood 103:966–972.
20. Boaz, M. J., A. Waters, S. Murad, P. J. Easterbrook, and A.
Vyakarnam. 2002. Presence of HIV-1 Gag-specific IFN-
gamma þ IL-2þ and CD28 þ IL-2þ CD4 T cell responses
is associated with nonprogression in HIV-1 infection. J.
Immunol. 169:6376–6385.
21. Casey, R., D. Blumenkrantz, K. Millington, D. Montamat-
Sicotte, O. M. Kon, M. Wickremasinghe, S. Bremang, M.
Magtoto, S. Sridhar, D. Connell, et al. 2010. Enumeration
of functional T-cell subsets by fluorescence-immunospot
defines signatures of pathogen burden in tuberculosis. PLoS
ONE 5:e15619.
22. Day, C. L., D. A. Abrahams, L. Lerumo, E. Janse van
Rensburg, L. Stone, T. O’Rie, B. Pienaar, M. de Kock, G.
Kaplan, H. Mahomed, et al. 2011. Functional capacity of
Mycobacterium tuberculosis-specific T cell responses in
humans is associated with mycobacterial load. J. Immunol.
187:2222–2232.
23. Lalvani, A., and K. A. Millington. 2008. T cells and tuber-
culosis: beyond interferon-gamma. J. Infect. Dis. 197:941–
943.
24. Lahey, T., S. Sheth, M. Matee, R. Arbeit, C. R. Horsburgh, L.
Mtei, T. Mackenzie, M. Bakari, J. M. Vuola, K. Pallangyo,
et al. 2010. Interferon gamma responses to mycobacterial
Immunity inflammation and disease K. M. Pollock et al.
152 © 2015 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
antigens protect against subsequent HIV-associated tubercu-
losis. J. Infect. Dis. 202:1265–1272.
25. Kalsdorf, B. T. J. Scriba, K. Wood, C. L. Day, K. Dheda, R.
Dawson, W. A. Hanekom, C. Lange, and R. J. Wilkinson.
2009. HIV-1 Infection impairs the bronchoalveolar T-Cell
Response to Mycobacteria. Am. J. Respir. Crit. Care Med.
180:1262–1270.
26. Chetoui, N., M. Boisvert, S. Gendron, and F. Aoudjit, 2010.
Interleukin-7 promotes the survival of human CD4þ
effector/memory T cells by up-regulating Bcl-2 proteins
and activating the JAK/STAT signalling pathway. Immunol-
ogy 130:418–426.
27. Schluns, K. S., and L. Lefrancois. 2003. Cytokine control of
memory T-cell development and survival. Nat. Rev. Immu-
nol. 3:269–279.
28. Appay, V., P. R. Dunbar, M. Callan, P. Klenerman, G. M.
Gillespie, L. Papagno, G. S. Ogg, A. King, F. Lechner, C. A.
Spina, et al. 2002. Memory CD8þ T cells vary in differen-
tiation phenotype in different persistent virus infections. Nat.
Med. 8:379–385.
29. Riou, C., F. Treurnicht, M. R. Abrahams, K. Mlisana, M. K.
Liu, N. Goonetilleke, R. Koup,M. Roederer, S. Abdool Karim,
G. de Bruyn, et al. 2012. Increased memory differentiation is
associated with decreased polyfunctionality for HIV but not
for cytomegalovirus-specific CD8þ T cells. J. Immunol.
189:3838–3847.
30. Libri, V. R. I. Azevedo, S. E. Jackson, D. Di Mitri, R.
Lachmann, S. Fuhrmann, M. Vukmanovic-Stejic, K. Yong, L.
Battistini, F. Kern, et al. 2011. Cytomegalovirus infection
induces the accumulation of short-lived, multifunctional
CD4þ CD45RAþ CD27þ T cells: the potential involvement
of interleukin-7 in this process. Immunology 132:326–
339.
31. Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central
memory and effector memory T cell subsets: function,
generation, and maintenance. Annu. Rev. Immunol. 22:745–
763.
32. Pollock, K. M., H. S. Whitworth, D. J. Montamat-Sicotte, L.
Grass, G. S. Cooke, M. S. Kapembwa, O. M. Kon, R. D.
Sampson, G. P. Taylor, and A. Lalvani. 2013. T-cell
immunophenotyping distinguishes active from latent tuber-
culosis. J. Infect. Dis. 208:952–968.
33. Freeman, G. J., E. J. Wherry, R. Ahmed, and A. H. Sharpe,
2006. Reinvigorating exhaustedHIV-specific T cells via PD-1-
PD-1 ligand blockade. J. Exp. Med. 203:2223–2227.
34. Porichis, F., D. S. Kwon, J. Zupkosky, D. P. Tighe, A.
McMullen, M. A. Brockman, D. F. Pavlik, M. Rodriguez-
Garcia, F. Pereyra, G. J. Freeman, et al. 2011. Responsiveness
of HIV-specific CD4 T cells to PD-1 blockade. Blood
118:965–974.
35. Jurado, J. O. I. B. Alvarez, V. Pasquinelli, G. J. Martinez, M. F.
Quiroga, E. Abbate, R. M. Musella, H. E. Chuluyan, and V. E.
Garcia. 2008. Programmed death (PD)-1:PD-ligand 1/PD-
ligand 2 pathway inhibits T cell effector functions during
human tuberculosis. J. Immunol. 181:116–125.
36. Lazar-Molnar, E. B. Chen, K. A. Sweeney, E. J. Wang, W. Liu,
J. Lin, S. A. Porcelli, S. C. Almo, S. G. Nathenson, and W. R.
Jacobs. , Jr. 2010. Programmed death-1 (PD-1)-deficient
mice are extraordinarily sensitive to tuberculosis. Proc. Natl.
Acad. Sci. U. S. A. 107:13402–13407.
37. Dosanjh, D. P., T. S. Hinks, J. A. Innes, J. J. Deeks, G.
Pasvol, S. Hackforth, H. Varia, K. A. Millington, R.
Gunatheesan, V. Guyot-Revol, et al. 2008. Improved
diagnostic evaluation of suspected tuberculosis. Ann. Intern.
Med. 148:325–336.
38. Amyes, E., C. Hatton, D. Montamat-Sicotte, N. Gudgeon,
A. B. Rickinson, A. J. McMichael, and M. F. Callan. 2003.
Characterization of the CD4þ T cell response to Epstein-Barr
virus during primary and persistent infection. J. Exp. Med.
198:903–911.
SUPPORTING INFORMATION
Additional supporting information may be found in the
online version of this article at the publisher’s web-site.
Figure S1. Differentiation status of CD4þ antigen-specific
functional subsets.
Figure S2. Frequency of CD4þ cell subsets that expressed
PD-1.
K. M. Pollock et al. Immunity inflammation and disease
© 2015 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 153
